cefuroxime has been researched along with Bronchitis, Chronic in 9 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Bronchitis, Chronic: A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized, double-blind, double-dummy trial was performed comparing 200 mg of cefditoren-pivoxil twice daily for 5 days versus standard cefuroxime-axetil treatment (250 mg twice daily for 10 days) of Anthonisen type I or II acute exacerbations of chronic bronchitis." | 9.12 | Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. ( Aguilar, L; Alvarez-Sala, JL; Coronel, P; Kardos, P; Martínez-Beltrán, J, 2006) |
| "To compare the effectiveness of oral moxifloxacin with standard antibiotic therapy in acute exacerbation of chronic bronchitis (AECB)." | 9.11 | Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. ( Allegra, L; Huchon, G; Izquierdo, JL; Jones, P; Sagnier, PP; Schaberg, T; Wilson, R, 2004) |
| ") ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274)." | 9.10 | Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. ( Ball, P; Bateman, K; Langan, C; Pypstra, R; Wilson, R, 2003) |
| "A pharmacoeconomic analysis was done to compare the efficiency of two treatments in the acute exacerbation of chronic bronchitis: telithromycin and cefuroxime-axetil." | 7.72 | [Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil]. ( Chang, J; Cots, JM; Domínguez-Gil, A; Herreras, A; Rubio-Terrés, C; Sánchez Gascón, F; Trilla, A, 2004) |
| "A randomized, double-blind, double-dummy trial was performed comparing 200 mg of cefditoren-pivoxil twice daily for 5 days versus standard cefuroxime-axetil treatment (250 mg twice daily for 10 days) of Anthonisen type I or II acute exacerbations of chronic bronchitis." | 5.12 | Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. ( Aguilar, L; Alvarez-Sala, JL; Coronel, P; Kardos, P; Martínez-Beltrán, J, 2006) |
| "To compare the effectiveness of oral moxifloxacin with standard antibiotic therapy in acute exacerbation of chronic bronchitis (AECB)." | 5.11 | Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. ( Allegra, L; Huchon, G; Izquierdo, JL; Jones, P; Sagnier, PP; Schaberg, T; Wilson, R, 2004) |
| ") ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days) in adult hospitalized patients with acute exacerbations of chronic bronchitis (AECB) (n = 274)." | 5.10 | Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. ( Ball, P; Bateman, K; Langan, C; Pypstra, R; Wilson, R, 2003) |
| "A pharmacoeconomic analysis was done to compare the efficiency of two treatments in the acute exacerbation of chronic bronchitis: telithromycin and cefuroxime-axetil." | 3.72 | [Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil]. ( Chang, J; Cots, JM; Domínguez-Gil, A; Herreras, A; Rubio-Terrés, C; Sánchez Gascón, F; Trilla, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weiss, LR | 1 |
| Wilson, R | 2 |
| Langan, C | 1 |
| Ball, P | 1 |
| Bateman, K | 1 |
| Pypstra, R | 1 |
| White, AJ | 1 |
| Gompertz, S | 1 |
| Bayley, DL | 1 |
| Hill, SL | 1 |
| O'Brien, C | 1 |
| Unsal, I | 1 |
| Stockley, RA | 1 |
| Allegra, L | 1 |
| Huchon, G | 1 |
| Izquierdo, JL | 1 |
| Jones, P | 1 |
| Schaberg, T | 1 |
| Sagnier, PP | 1 |
| Rubio-Terrés, C | 1 |
| Cots, JM | 1 |
| Domínguez-Gil, A | 1 |
| Herreras, A | 1 |
| Sánchez Gascón, F | 1 |
| Chang, J | 1 |
| Trilla, A | 1 |
| Alvarez-Sala, JL | 1 |
| Kardos, P | 1 |
| Martínez-Beltrán, J | 1 |
| Coronel, P | 1 |
| Aguilar, L | 1 |
| Petitpretz, P | 1 |
| Choné, C | 1 |
| Trémolières, F | 1 |
| Haczyński, J | 1 |
| Chyczewska, E | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Malolepszy, J | 1 |
| Marcinkowska-Suchowierska, E | 1 |
| Milanowski, J | 1 |
| Oklek, K | 1 |
| Płusa, T | 1 |
| Słominski, J | 1 |
| Szmygin, K | 1 |
| Rek, M | 1 |
6 trials available for cefuroxime and Bronchitis, Chronic
| Article | Year |
|---|---|
Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchit | 2002 |
Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefurox | 2004 |
Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.
Topics: Acute Disease; Administration, Oral; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Cefuroxime; C | 2006 |
Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval.
Topics: Aged; Bronchitis, Chronic; Cefuroxime; Female; Heart Failure; Humans; Levofloxacin; Male; Middle Age | 2007 |
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Bronchitis, Chronic; Cefaclor; Cefuroxime; Cephalosporins; Female; H | 2002 |
3 other studies available for cefuroxime and Bronchitis, Chronic
| Article | Year |
|---|---|
Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Biomarkers; Bronchitis, | 2003 |
[Acute exacerbated chronic bronchitis. Antibiotics in comparison].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; C | 2003 |
[Pharmacoeconomic analysis of patients with acute exacerbation of chronic bronchitis treated with telithromycin or cefuroxime-axetil].
Topics: Acute Disease; Algorithms; Anti-Bacterial Agents; Bronchitis, Chronic; Cefuroxime; Cost-Benefit Anal | 2004 |